• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Neuroene Therapeutics

Wednesday, June 05, 2024
Start-Up Stadium Session
CNS/Neurological
Neuroene is developing mitochondrial-protective small molecules for epilepsy, Parkinson's and mitochondrial diseases. Our lead clinical candidate has FDA Orphan Drug Designation for Dravet syndrome, a rare childhood epilepsy with striking efficacy as a monotherapy in many animal seizure models, and works as an adjunct with additive antiseizure activity with no adverse drug-drug effects so far. Our candidate is well-tolerated, brain-penetrating, fast-acting and targets a new mechanism of action (mitochondrial protection) that is differentiated and complementary to current antiseizure medications. We seek $10M for IND-enabling studies and Phase I trials. We previously won the 2022 BioHealth Capital Region pitch competition.
Company Website: https://NeuroeneTherapeutics.com

Company HQ City

Kensington

Company HQ State

MD

Company HQ Country

United States

CEO/Top Company Official

Sherine Chan
Speakers
Sherine Chan
CEO and Co-Founder
Neuroene Therapeutics
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS